Literature DB >> 25979073

Plasma Kallikrein-Kinin System as a VEGF-Independent Mediator of Diabetic Macular Edema.

Takeshi Kita1, Allen C Clermont1, Nivetha Murugesan1, Qunfang Zhou1, Kimihiko Fujisawa2, Tatsuro Ishibashi2, Lloyd Paul Aiello3, Edward P Feener4.   

Abstract

This study characterizes the kallikrein-kinin system in vitreous from individuals with diabetic macular edema (DME) and examines mechanisms contributing to retinal thickening and retinal vascular permeability (RVP). Plasma prekallikrein (PPK) and plasma kallikrein (PKal) were increased twofold and 11.0-fold (both P < 0.0001), respectively, in vitreous from subjects with DME compared with those with a macular hole (MH). While the vascular endothelial growth factor (VEGF) level was also increased in DME vitreous, PKal and VEGF concentrations do not correlate (r = 0.266, P = 0.112). Using mass spectrometry-based proteomics, we identified 167 vitreous proteins, including 30 that were increased in DME (fourfold or more, P < 0.001 vs. MH). The majority of proteins associated with DME displayed a higher correlation with PPK than with VEGF concentrations. DME vitreous containing relatively high levels of PKal and low VEGF induced RVP when injected into the vitreous of diabetic rats, a response blocked by bradykinin receptor antagonism but not by bevacizumab. Bradykinin-induced retinal thickening in mice was not affected by blockade of VEGF receptor 2. Diabetes-induced RVP was decreased by up to 78% (P < 0.001) in Klkb1 (PPK)-deficient mice compared with wild-type controls. B2- and B1 receptor-induced RVP in diabetic mice was blocked by endothelial nitric oxide synthase (NOS) and inducible NOS deficiency, respectively. These findings implicate the PKal pathway as a VEGF-independent mediator of DME.
© 2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25979073      PMCID: PMC4587649          DOI: 10.2337/db15-0317

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  48 in total

1.  Expression and cellular localization of the kallikrein-kinin system in human ocular tissues.

Authors:  J X Ma; Q Song; H C Hatcher; R K Crouch; L Chao; J Chao
Journal:  Exp Eye Res       Date:  1996-07       Impact factor: 3.467

Review 2.  Pathways for bradykinin formation and inflammatory disease.

Authors:  Allen P Kaplan; Kusumam Joseph; Michael Silverberg
Journal:  J Allergy Clin Immunol       Date:  2002-02       Impact factor: 10.793

3.  Ecallantide for the treatment of acute attacks in hereditary angioedema.

Authors:  Marco Cicardi; Robyn J Levy; Donald L McNeil; H Henry Li; Albert L Sheffer; Marilyn Campion; Patrick T Horn; William E Pullman
Journal:  N Engl J Med       Date:  2010-08-05       Impact factor: 91.245

4.  The kallikrein system in retinal damage/protection.

Authors:  Tomomi Masuda; Masamitsu Shimazawa; Hideaki Hara
Journal:  Eur J Pharmacol       Date:  2014-10-18       Impact factor: 4.432

5.  Proteomic identification of novel plasma kallikrein substrates in the astrocyte secretome.

Authors:  Jia Liu; Ben-Bo Gao; Edward P Feener
Journal:  Transl Stroke Res       Date:  2010-08-28       Impact factor: 6.829

6.  Endothelial nitric-oxide synthase activation generates an inducible nitric-oxide synthase-like output of nitric oxide in inflamed endothelium.

Authors:  Jessica L Lowry; Viktor Brovkovych; Yongkang Zhang; Randal A Skidgel
Journal:  J Biol Chem       Date:  2012-12-19       Impact factor: 5.157

7.  Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema.

Authors:  Hideharu Funatsu; Hidetoshi Yamashita; Tomohiro Ikeda; Tatsuya Mimura; Shuichiro Eguchi; Sadao Hori
Journal:  Ophthalmology       Date:  2003-09       Impact factor: 12.079

8.  Critical role of inducible nitric oxide synthase in degeneration of retinal capillaries in mice with streptozotocin-induced diabetes.

Authors:  L Zheng; Y Du; C Miller; R A Gubitosi-Klug; T S Kern; S Ball; B A Berkowitz
Journal:  Diabetologia       Date:  2007-06-22       Impact factor: 10.122

9.  Misfolded proteins activate factor XII in humans, leading to kallikrein formation without initiating coagulation.

Authors:  Coen Maas; José W P Govers-Riemslag; Barend Bouma; Bettina Schiks; Bouke P C Hazenberg; Henk M Lokhorst; Per Hammarström; Hugo ten Cate; Philip G de Groot; Bonno N Bouma; Martijn F B G Gebbink
Journal:  J Clin Invest       Date:  2008-09       Impact factor: 14.808

10.  Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.

Authors:  L P Aiello; R L Avery; P G Arrigg; B A Keyt; H D Jampel; S T Shah; L R Pasquale; H Thieme; M A Iwamoto; J E Park
Journal:  N Engl J Med       Date:  1994-12-01       Impact factor: 91.245

View more
  24 in total

Review 1.  Future opportunities in diabetic retinopathy research.

Authors:  Thomas W Gardner; Emily Y Chew
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2016-04       Impact factor: 3.243

2.  Investigational plasma kallikrein inhibitors for the treatment of diabetic macular edema: an expert assessment.

Authors:  Ashay D Bhatwadekar; Viral S Kansara; Thomas A Ciulla
Journal:  Expert Opin Investig Drugs       Date:  2020-01-31       Impact factor: 6.206

Review 3.  The role of inflammation in diabetic eye disease.

Authors:  Marina Mesquida; Faye Drawnel; Sascha Fauser
Journal:  Semin Immunopathol       Date:  2019-06-07       Impact factor: 9.623

4.  Expression, distribution and function of kinin B1 receptor in the rat diabetic retina.

Authors:  Soumaya Hachana; Menakshi Bhat; Jacques Sénécal; Frédéric Huppé-Gourgues; Réjean Couture; Elvire Vaucher
Journal:  Br J Pharmacol       Date:  2018-02-13       Impact factor: 8.739

Review 5.  Molecules related to diabetic retinopathy in the vitreous and involved pathways.

Authors:  Hua-Qin Xia; Jia-Rui Yang; Ke-Xin Zhang; Rui-Lan Dong; Hao Yuan; Yu-Chen Wang; Hong Zhou; Xue-Min Li
Journal:  Int J Ophthalmol       Date:  2022-07-18       Impact factor: 1.645

Review 6.  Changes in aqueous and vitreous inflammatory cytokine levels in proliferative diabetic retinopathy: a systematic review and meta-analysis.

Authors:  Ryan H Mason; Samuel A Minaker; Gabriela Lahaie Luna; Priya Bapat; Armin Farahvash; Anubhav Garg; Nishaant Bhambra; Rajeev H Muni
Journal:  Eye (Lond)       Date:  2022-06-07       Impact factor: 4.456

7.  Earliest Evidence of Preclinical Diabetic Retinopathy Revealed Using Optical Coherence Tomography Angiography Perfused Capillary Density.

Authors:  Richard B Rosen; Jorge S Andrade Romo; Brian D Krawitz; Shelley Mo; Amani A Fawzi; Rachel E Linderman; Joseph Carroll; Alexander Pinhas; Toco Y P Chui
Journal:  Am J Ophthalmol       Date:  2019-01-26       Impact factor: 5.258

8.  The effects of anti-VEGF and kinin B1 receptor blockade on retinal inflammation in laser-induced choroidal neovascularization.

Authors:  Soumaya Hachana; Olivier Fontaine; Przemyslaw Sapieha; Mark Lesk; Réjean Couture; Elvire Vaucher
Journal:  Br J Pharmacol       Date:  2020-02-04       Impact factor: 8.739

Review 9.  Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group.

Authors:  Winfried M Amoaku; Faruque Ghanchi; Clare Bailey; Sanjiv Banerjee; Somnath Banerjee; Louise Downey; Richard Gale; Robin Hamilton; Kamlesh Khunti; Esther Posner; Fahd Quhill; Stephen Robinson; Roopa Setty; Dawn Sim; Deepali Varma; Hemal Mehta
Journal:  Eye (Lond)       Date:  2020-06       Impact factor: 3.775

10.  Interleukin-6 Trans-signaling: A Pathway With Therapeutic Potential for Diabetic Retinopathy.

Authors:  Shruti Sharma
Journal:  Front Physiol       Date:  2021-05-19       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.